Akoya Biosciences, Inc. (AKYA)
USD 2.45
(-3.54%)
USD 2.45
(-3.54%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 104.27 Million USD | -4.86% |
| 2022 | 109.59 Million USD | 53.41% |
| 2021 | 71.44 Million USD | 91.02% |
| 2020 | 37.4 Million USD | -2.01% |
| 2019 | 38.16 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 24.38 Million USD | -4.07% |
| 2024 Q1 | 25.41 Million USD | 7.85% |
| 2023 Q4 | 23.56 Million USD | -2.57% |
| 2023 FY | 104.27 Million USD | -4.86% |
| 2023 Q3 | 24.19 Million USD | -21.53% |
| 2023 Q2 | 30.82 Million USD | 4.49% |
| 2023 Q1 | 29.5 Million USD | 1.24% |
| 2022 Q2 | 27.8 Million USD | 9.25% |
| 2022 Q1 | 25.45 Million USD | -2.05% |
| 2022 FY | 109.59 Million USD | 53.41% |
| 2022 Q4 | 29.14 Million USD | 7.12% |
| 2022 Q3 | 27.2 Million USD | -2.17% |
| 2021 Q1 | 12.38 Million USD | 19.37% |
| 2021 FY | 71.44 Million USD | 91.02% |
| 2021 Q4 | 25.98 Million USD | 36.98% |
| 2021 Q3 | 18.96 Million USD | 34.41% |
| 2021 Q2 | 14.11 Million USD | 13.99% |
| 2020 FY | 37.4 Million USD | -2.01% |
| 2020 Q4 | 10.37 Million USD | 15.72% |
| 2020 Q3 | 8.96 Million USD | 6.1% |
| 2020 Q2 | 8.44 Million USD | -12.19% |
| 2020 Q1 | 9.62 Million USD | 0.0% |
| 2019 FY | 38.16 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AngioDynamics, Inc. | 252.41 Million USD | 58.691% |
| AtriCure, Inc. | 327.05 Million USD | 68.118% |
| Avinger, Inc. | 18.63 Million USD | -459.448% |
| Azenta, Inc. | 336.26 Million USD | 68.992% |
| BioLife Solutions, Inc. | 117.57 Million USD | 11.318% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 94.286% |
| Daxor Corporation | 1.28 Million USD | -8042.818% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -331.028% |
| Femasys Inc. | 15.2 Million USD | -585.973% |
| GlucoTrack, Inc. | 7.1 Million USD | -1367.765% |
| Harvard Bioscience, Inc. | 58.58 Million USD | -77.993% |
| Hologic, Inc. | 1.34 Billion USD | 92.249% |
| ICU Medical, Inc. | 717.04 Million USD | 85.458% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 96.481% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -299.381% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | -15.423% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 87480.268% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 87480.268% |
| Masimo Corporation | 867 Million USD | 87.973% |
| Microbot Medical Inc. | 9.85 Million USD | -958.042% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -466.068% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 77.329% |
| Nephros, Inc. | 9.78 Million USD | -965.72% |
| NovoCure Limited | 613.92 Million USD | 83.016% |
| NEXGEL, Inc. | 4.09 Million USD | -2445.654% |
| NEXGEL, Inc. | 4.09 Million USD | -2445.654% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | -1.983% |
| OraSure Technologies, Inc. | 125.34 Million USD | 16.812% |
| Pro-Dex, Inc. | 7.37 Million USD | -1313.256% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -139.294% |
| Predictive Oncology Inc. | 15.22 Million USD | -584.657% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -1123.523% |
| QuidelOrtho Corporation | 1.35 Billion USD | 92.307% |
| Repligen Corporation | 261.12 Million USD | 60.069% |
| Sanara MedTech Inc. | 61.12 Million USD | -70.579% |
| STAAR Surgical Company | 224.55 Million USD | 53.566% |
| Sharps Technology, Inc. | 10.12 Million USD | -929.659% |
| Utah Medical Products, Inc. | 13.26 Million USD | -686.291% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 94.188% |
| Jin Medical International Ltd. | 3.91 Million USD | -2561.598% |